ORIGINAL PAPER
Leiomyoma cellulare in postoperative material: clinical cases
Publication date: 2013-08-05
Medical Studies 2013;29(2):144-151
KEYWORDS
ABSTRACT
Introduction: Leiomyoma in one of the most common benign endometrial cancers. Location of the myoma in the cervix and the area of the broad ligament of the uterus is rare. Leiomyoma cellulare (LC) occurs in about 5.0% of leiomyoma cases.
Aim of the research: To determine the occurrence of LC among 294 cases of myomas as well as myomas and uterine endometriosis, found in postoperative examinations.
Material and methods: Patients were qualified for the surgery based on a gynaecological examination, an ultrasonographic examination and a histological assessment of scrapings from the uterine cavity. The final diagnosis was given at the Centre of Pathomorphology of the Radom Specialist Hospital in Radom, based on a microscopic examination of postoperative material. Clinical analysis was performed in 16 cases, where LC was diagnosed during postoperative examination.
Results: Among the women operated on due to myomas (n = 179; 60.9%) as well as myomas and reproductive organ endometriosis (n = 115; 39.1%), LC tissue was diagnosed during histopathological examination in 9 (5.0%) and 7 (6.1%) cases, respectively. The average age of the LC patients was 45.6, whereas in patients with myomas as well as myomas and reproductive organ endometriosis it was 49.1. The average age of LC patients was significantly lower in relation to patients operated on due to reproductive organ myomas. In 87.5% of the cases, LC was found in myomas situated in the body of the uterus; and in the remaining 12.5% (2 cases), in the cervix and the area of the parametrium.
Conclusions: Leiomyoma cellulare in reproductive organs concerned mainly the body of the uterus (87.4%), and sporadically the cervix (6.3%) and the area of the broad ligament of the uterus (6.3%).
Aim of the research: To determine the occurrence of LC among 294 cases of myomas as well as myomas and uterine endometriosis, found in postoperative examinations.
Material and methods: Patients were qualified for the surgery based on a gynaecological examination, an ultrasonographic examination and a histological assessment of scrapings from the uterine cavity. The final diagnosis was given at the Centre of Pathomorphology of the Radom Specialist Hospital in Radom, based on a microscopic examination of postoperative material. Clinical analysis was performed in 16 cases, where LC was diagnosed during postoperative examination.
Results: Among the women operated on due to myomas (n = 179; 60.9%) as well as myomas and reproductive organ endometriosis (n = 115; 39.1%), LC tissue was diagnosed during histopathological examination in 9 (5.0%) and 7 (6.1%) cases, respectively. The average age of the LC patients was 45.6, whereas in patients with myomas as well as myomas and reproductive organ endometriosis it was 49.1. The average age of LC patients was significantly lower in relation to patients operated on due to reproductive organ myomas. In 87.5% of the cases, LC was found in myomas situated in the body of the uterus; and in the remaining 12.5% (2 cases), in the cervix and the area of the parametrium.
Conclusions: Leiomyoma cellulare in reproductive organs concerned mainly the body of the uterus (87.4%), and sporadically the cervix (6.3%) and the area of the broad ligament of the uterus (6.3%).
REFERENCES (70)
1.
Auguściak-Duma A, Sieroń AL. Molekularna charakterystyka guzów leiomyoma uteri na przykładzie wybranych składników macierzy pozakomórkowej. Postępy Hig Med Dośw 2008; 62: 148–165.
2.
Dębski R, Kotarski J, Paszkowski T i wsp. Stanowisko Zespołu Ekspertów Polskiego Towarzystwa Ginekologicznego w sprawie zastosowania selektywnych modulatorów receptora progesteronowego (SPRM) w leczeniu mięśniaków macicy. Ginekol Pol 2012; 83: 555–557.
3.
Jakowicki JA. Onkologia ginekologiczna. Nowotwory ma¬cicy. W: Vademecum diagnostyki ginekologicznej. Red. JA Jakowicki. Wydawnictwo Biforium, Lublin 2009; 118–121.
4.
Ligon AH, Morton CC. Genetics of uterine leiomyoma. Genes Chromosomes Cancer 2000; 28: 235–245.
5.
Stewart EA, Morton CC. The genetics of uterine leiomyomata: what clinicians need to know. Obstet Gynecol 2006; 107: 917–921.
6.
Lobel MK, Somasundaram P, Morton CC. The genetic heterogeneity of uterine leiomyomata. Obstet Gynecol Clin North Am 2006; 33: 13–39.
7.
.Gross KL, Morton CC. Genetics and the development of fibroids. Clin Obstet Gynecol 2001; 44: 335–349.
8.
Chang CC, Hsieh YY, Lin WH et al. Leiomyoma and vascular endothelial growth factor gene polymorphisms: a systematic review. Taiwan J Obstet Gynecol 2010; 49: 247–253.
9.
Toro JR, Nickerson ML, Wei MH et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomas and renal cell cancer in families in North America. Am J Hum Genet 2003; 73: 95–106.
10.
Kiuru M, Launonen V, Hietala M et al. Familian cutaneous leiomyomatosis is a two hit condition associated with renal cell cancer of characteristic histopathology. Am.
12.
Tomlinson IP, Alam NA, Rowan AJ et al. The multiple Leiomyoma Consortium Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30: 406–410.
13.
Luo X, Ding L, Xu J et al. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology 2007; 146: 1097–1118.
14.
.Laping NJ, Everitt JI, Frazier KS et al. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res 2007; 13: 3087–3099.
15.
Halder SK, Goodwin JS, Al-Hendy A. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in hu¬man uterine leiomyoma cells. J Clin Endocrinol Metab 2011; 96: E754–E762.
16.
Norian JM, Malik M, Parker CY et al. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci 2009; 16: 1153–1164.
17.
Sozen I, Arici A. Interaction of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterinae leiomyomata. Fertil Steril 2002; 78: 1–12.
18.
Al-Hendy A, Salama S. Gene therapy and uterine leiomyoma: a review. Human Reprod Update 2006; 12: 385–400.
19.
.Chmaj-Wierzchowska K, Buks J, Wierzchowski M et al. Leiomyoma cellulare in the broad ligament of the uterus – case report and review of literature. Ginekol Pol 2012; 83: 301–304.
20.
Wei C, Lilic N, Shorter N et al. Primary ovarian leiomyoma: a rare causa of ovarian tumor in adolescence. J Pediatr Adolesc Gynecol 2008; 21: 33–36.
21.
Lim SC, Jeon HJ. Bilateral primary ovarian leiomyoma in a young woman: case report and literature review. Gynecol Oncol 2004; 95: 733–735.
22.
Canevari RA, Pontes A, Rosa FE et al. Independent clonal origin of multiple uterine leiomyomas that was determined by X chromosome inactivation and microsatellite analysis. Am J Obstet Gynecol 2005; 193: 1395–1403.
23.
Fernandes H, Naik CN, Swethadri GK et al. Pure lipoma of the uterus: a rare case report. Indian J Pathol Microbiol 2007; 50: 800–801.
24.
.Katz VL, Dotters DJ, Droegemueller W. Complications of uterine leiomyomas in pregnancy. Obstet Gynecol 1989; 73: 593–596.
25.
Nowicka J, Sowińska E, Floriański J i wsp. Odczyn białaczkowy u ciężarnej w przebiegu stanu zapalnego mięśniaka macicy i zakażenia układu moczowego. Ginekol Pol 2004; 75: 874–878.
26.
.Panek G. Nienabłonkowe nowotwory trzonu macicy (mięśniaki i mięsaki). W: Ginekologia onkologiczna. Tom 2.
28.
Banaczek Z, Sikora K, Lewandowska-Andruszuk I. Występowanie leiomyoma cellulare w materiale pooperacyjnym w Oddziale Ginekologiczno-Położniczym w WSzS w Radomiu. Ginekol Pol 2004; 75: 858–862.
29.
.Knapp P, Chabowski A. Molekularne i cytogenetyczne podstawy rozwoju mięśniaków macicy. Postepy Hig Med Dośw 2012; 66: 23–32.
30.
Andersen J. Comparing regulation of the connexin 43 gene by estrogen in uterine leiomyoma and pregnancy myometrium. Environ Health Perspect 2000; 108 (Suppl. 5): 811–815.
31.
.El-Shennawy GA, Elbialy AA, Isamil AE et al. Is genetic polymorphism of ER-a, CYP1A1, and CYP1B1 a risk factor for uterine leiomyoma? Arch Gynecol Obstet 2011; 283: 1313–1318.
32.
Zeng WR, Scherer SW, Koutsilieris M et al. Loss of heterozygosity and reduced expression of the CUTL1 gene in uterine leiomyomas. Oncogene 1997; 14: 2355–2365.
33.
Sung CO, Ahn G, Song SY. Atypical leiomyomas of the uterus with long-term follow-up after myomectomy with immunohistochemical analysis for p16INK4A, p53, Ki-67, estrogen receptors, and progesterone receptors. Int J Gynecol Pathol 2009; 28: 529–534.
34.
.Bodner-Adler B, Bodner K, Czerwenka K et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol 2005; 96: 62–66.
35.
.O’Neill CJ, McBride HA, Connolly LE et al. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology 2007; 50: 851–858.
36.
Ligon AH, Morton CC. Leiomyomata: heritability and cytogenetic studies. Hum Reprod Update 2001; 7: 8–14.
37.
Van Rijk A, Sweers M, Huys E et al. Characterization of a recurrent t (1;2)(p36;p24) in human uterine leiomyoma. Cancer Gene Cytogenet 2009; 193: 54–62.
38.
.Stumm M, Neubauer S, Keindorff S et al. High frequency of spontaneous translocations revealed by FISH in cells from patients with the cancer-prone syndromes ataxia teleangiectasia and Nijmegen breakage syndrome. Cytogenet Cell Genet 200l; 92: 186–191.
39.
.Czapczak D, Markowska A, Piątkowska M i wsp. Nosicielstwo mutacji w eksonie 6 genu NBS1 a ryzyko zachorowania na mięśniaki macicy. Nowotwory J Onkol 2011; 61: 109–113.
40.
Darling TN, Pacheco-Rodriguez G, Gorio A et al. Lymph-angioleiomyomatosis and TSC2-/- cells. Lymphat Res Biol 2010; 8: 59–69.
41.
Peng L, Wen Y, Han Y et al. Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. Fertil Steril 2009; 91: 2664–2675.
42.
Peng Y, Laser J, Shi G et al. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 2008; 6: 663–673.
43.
Uliana V, Marcocci E, Mucciolo M et al. Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2. Pediatr Nephrol 2011; 26: 717–724.
44.
Rein MS, Powell WL, Walters FC et al. Cytogenetic abnormalities in uterine myomas are associated with myoma size. Hum Mol Reprod 1998; 4: 83–86.
45.
.Brosens I, Deprest J, Dal Cin P et al. Clinical significance of cytogenetic abnormalities in uterine myomas. Fertil Steril 1998; 69: 232–235.
46.
.Taran FA, Weaver AL, Gostout BS et al. Understanding cellular leiomyomas: a case-control study. Am J Obstet Gynecol 2010; 203: 109.e1–6.
47.
Guan R, Zheng W, Xu M. A retrospective analysis of the clinicopathologic characteristics of uterine cellular leiomyomas in China. Int J Gynecol Obstet 2012; 118: 52–55.
48.
Oliva E, Young RH, Amin MB et al. An immunohistochemical analysis of endometrial stromal and smoth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002; 26: 403–412.
49.
.Zhu XQ, Shi YF, Cheng XD et al. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol 2004; 92: 71–79.
50.
Hoffman PJ, Milliken DB, Gregg LC et al. Molecular cha¬racterization of uterine fibroids and its complication for underlying mechanisms of pathogenesis. Fertil Steril 2004; 82: 639–649.
51.
.Chang CC, Hsieh YY, Lin WH et al. Leiomyoma and vascular endothelial growth factor gene polymorphisms: a systematic review. Taiwan J Obstet Gynecol 2010; 49: 247–253.
52.
.Lewicka A, Osuch B, Cendrowski K et al. Expression of vascular endothelial growth factor mRNA in human leiomyomas. Gynecol Endocrinol 2010; 26: 451–455.
53.
Nakayama T, Cho YC, Mine Y et al. Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas. World J Gastroenterol 2006; 12: 6182–6187.
54.
.Takeda T, Osuga K, Miyake A et al. Elevated level of plasma vascular endothelial growth factor after gonadotropin-releasing hormone agonist treatment for leiomyomata. Gynecol Endocrinol 2008; 24: 724–726.
55.
Di Lieto A, De Falco M, Mansueto G et al. Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern. Steroids 2005; 70: 95–102.
56.
Di Lieto A, De Falco M, Pollio F et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig 2005; 12: 123–128.
57.
.Dixon D, He H, Haseman JK. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect 2000; 108 (Suppl. 5): 795–802.
58.
.Bodner K, Bodner-Adler B, Kimberger O et al. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. J Soc Gynecol Investig 2004; 11: 187–191.
59.
Luo X, Chegini N. The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma. Semin Reprod Med 2008; 26: 500–514.
60.
Luo X, Pan Q, Liu L et al. Genomic and proteomic profiling II: comparative assessment of gene expression profiles in leiomyomas, keloids, and surgically-induced scars. Reprod Biol Endocrinol 2007; 5: 35.
61.
Nieman LK, Blocker W, Nansel T et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril 2011; 95: 767–772.
63.
Szajda SD, Jóźwik M, Sułkowska M et al. Analysis of the relationship between cancesr procoagulant activity and PCNA and mKi-67 expresion in cases of common and cellular uterine leiomyomas. Eur J Gynaecol Oncol 2006; 27: 495–499.
64.
.Maruo T, Ohara N, Yoshida S et al. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system. Contraception 2010; 82: 435–441.
65.
.Michalska M, Spaczyński M, Sajdak S. Nowotwory mezenchymalne trzonu macicy. W: Onkologia ginekologiczna. Red. M Spaczyński. Urban&Partner, Wrocław 1997; 197–201.
66.
.McDonald AG, Dal Cin P, Ganguly A et al. Liposarcoma arising in uterine lipoleiomyoma: a report of 3 cases.
68.
.Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. Obstet Gynecol 2002; 99: 229–234.
69.
.Sikora-Szczęśniak DL. Śródpowięziowe pochwowo-brzuszne wycięcie macicy. Ginekol Prakt 2003; 11: 36–38.
70.
Hassan MH, Salama SA, Zhang D et al. Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril 2010; 93: 239–250.
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
